SCHEMBL1329344

SCHEMBL1329344

CC(C)(C)NC(=O)Cc1ccccc1C#Cc1ccnc2[nH]ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 7/20 0.41
NUDT1 P36639 2/20 0.40
ROCK1 Q13464 2/20 0.38
DGAT2 Q96PD7 1/20 0.38
AURKB Q96GD4 2/20 0.36
AURKA O14965 1/20 0.36
PTK2 Q05397 2/20 0.35
RET P07949 2/20 0.35
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
CSF1R P07333 1/20 0.35
IGF1R P08069 1/20 0.35
FGFR1 P11362 1/20 0.35
PRKACA P17612 1/20 0.35
FLT1 P17948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1328371 0.87 ANO1 (0.40) ANO1NUDT1ROCK1DGAT2AURKB
SCHEMBL1328116 0.84 NUDT1 (0.44) NUDT1ROCK1AURKBPTK2RET
SCHEMBL1327513 0.83 NUDT1 (0.37) NUDT1ROCK1DGAT2AURKBAURKA
SCHEMBL1327987 0.81 PTK2 (0.43) NUDT1ROCK1AURKBPTK2RET
SCHEMBL12127430 0.81 NUDT1 (0.56) ANO1NUDT1ROCK1DGAT2AURKB
SCHEMBL1328693 0.80 JAK1 (0.41) NUDT1JAK2JAK3CYP1A2
SCHEMBL1328094 0.80 SMN1; SMN2 (0.48) ROCK1KDM4ELMNACYP1A2CYP3A4
SCHEMBL27847620 0.79 NUDT1 (0.38) NUDT1ROCK1AURKBPTK2RET
SCHEMBL1328769 0.79 NPC1 (0.52) RETKDM4EMAPTCYP2C9CYP2C19
SCHEMBL1327972 0.79 IKBKB (0.47) NUDT1ROCK1AURKBPTK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110282056-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-11-17 US claimed
EP-2231282-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF Merck Patent GmbH (DE) 2010-09-29 EP claimed
WO-2009094123-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-07-30 WO claimed
US-20110282056-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-11-17 US disclosed
US-20110282056-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282056-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP3K19, MAP3K20, MAP3K1 ANO1 3626/4885NUDT1 3161/4885ROCK1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.